The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection
Aidouni et al.,
The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19..,
Research Square, doi:10.21203/rs.3.rs-2313880/v1 (Preprint)
Prospective study of 1,124 COVID-19 ICU patients, showing lower mortality with aspirin treatment.
risk of death, 30.9% lower, HR 0.69, p = 0.003, treatment 202 of 712 (28.4%), control 165 of 412 (40.0%), NNT 8.6, adjusted per study, multivariable, Cox proportional hazards.
|
risk of mechanical ventilation, 9.6% lower, RR 0.90, p = 0.33, treatment 189 of 712 (26.5%), control 121 of 412 (29.4%), NNT 35.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Aidouni et al., 30 Nov 2022, prospective, Morocco, preprint, mean age 64.0, 6 authors, study period March 2020 - March 2022.
Contact:
aminbouchlarhem63@gmail.com.
Abstract: The impact of asprin use on the outcome of
patients admitted to the intensive care unit with
COVID-19 infection
Ghizlane El Aidouni ( aminbouchlarhem63@gmail.com )
Mohammed I st University
Amine Bouchlarhem
Mohammed I st University
Houssam Bkiyar
Mohammed I st University
Nabila Ismaili
Mohammed I st University
Noha El Ouafi
Mohammed I st University
Brahim housni
Mohammed I st University
Research Article
Keywords: Covid-19, Aspirin, Mortality, Thrombo-embolic events
Posted Date: November 30th, 2022
DOI: https://doi.org/10.21203/rs.3.rs-2313880/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Page 1/14
Abstract
Background
Our objective in this study is to know the impact of the use of asprin in anti-aggregation dose on the
evolution during hospitalization of patients admitted in intensive care unit for a severe infection by SARSCOV-2.
Methods
We conducted a prospective study of patients admitted to our department with severe COVID-19 infection
during the period between March 2020 and March 2022, analyzing the difference between the placebo
group and the aspirin group on the primary endpoint of all-cause hospital mortality and the composite
secondary endpoint of use of mechanical ventilation and thromboembolic events.
Results
Out of 1124 patients included, 32.6% died, with a protective effect of aspirin against placebo (Hazardratio = 0.691, p = 0.003), for thrombo-embolic complications, 104 events were observed, with a protective
effect of aspirin (Hazard-Ratio = 0.448 and p = 0.001), finally regarding mechanical ventilation, there was
no remarkable benefit on our sample.
Conclusion
Given the divergence of results of studies published in the literature, the availability of results of large
randomized controlled trials is a necessity.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit